Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Royalty Pharma plc Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes ...